Document:

EX-10.2

Exhibit 10.2

Waiver and Third Amendment to Investor Rights Agreement,
dated as of September 21, 2005 (this “Amendment”), among
Memory Pharmaceuticals Corp. (the “Company”) and the
investors set forth on the signature page hereto (the “Investors”)

The Company and the Investors entered into a Fourth Amended and Restated Investor Rights
Agreement dated as of September 11, 2003, as amended by an Agreement dated as of December 18, 2003,
among the Company, Dr. Eric Kandel and the Investors, an Amendment dated as of March 15, 2004 among
the Company and the Investors and an Amendment dated as of April 1, 2004 (the “Investor Rights
Agreement”). Capitalized terms used and not otherwise defined herein shall have the meanings
ascribed to such terms in the Investor Rights Agreement.

On April 4, 2004, the Company completed an Initial Public Offering and in connection therewith
each share of outstanding Preferred Stock was converted into shares of Common Stock. The Company
is considering entering into one or more transactions in which it would offer and sell equity or
equity-linked securities by private placement in accordance with the exemption from the
registration requirements of the Securities Act of 1933, as amended (the “Private Placement”). It
is expected that following the closing of the Private Placement, the Company will file a
registration statement (the “Resale Registration Statement”) with the Securities and Exchange
Commission for the resale from time to time of the securities issued in connection with the Private
Placement.

The Company and the Investors wish to amend the Investor Rights Agreement in certain respects
to (i) reflect the occurrence of the Initial Public Offering, (ii) waive the application of certain
rights of the Investors, and (iii) make other conforming changes.

The Company and the Investors hereby agree as follows:

1. Amendments to Investor Rights Agreement.

(a) The definition of “Registrable Securities” included in Section 1.3 of the Investor Rights
Agreement is hereby amended by deleting such definition in its entirety and replacing it with the
following:

“Registrable Securities” shall mean (i) shares of Common Stock issued pursuant to the
conversion of the Preferred Stock or issued or issuable pursuant to the exercise of the
Warrant; and (ii) any shares of Common Stock or other securities issued or issuable with
respect to such shares of Common Stock, the Preferred Stock or the Warrant by reason of any
stock split, stock dividend, recapitalization, reorganization, merger, consolidation, sale
of assets or similar event, excluding in any event securities that (a) have been registered
under the Securities Act pursuant to an effective registration statement filed thereunder
and disposed of in accordance with the registration statement covering them or (b) may be
publicly sold in any 90 day period pursuant to Rule 144 or any successor exemption under the
Securities Act. Wherever reference is made in this Agreement to a request or consent of
holders of a certain percentage of Registrable Securities, the determination of such
percentage shall be calculated on the basis of shares of Common Stock issued or issuable
upon exercise of the Warrant even if such exercise has not been effected.

(b) Section 4.12 of the Investor Rights Agreement is hereby deleted in its entirety.

(c) Section 8.3 of the Investor Rights Agreement is hereby amended by deleting Section 8.3 in
its entirety and replacing it with the following:

“8.3 Modifications and Amendments. This Agreement may not be amended or
modified, and no provision hereof may be waived, without the written consent of the Company
and the holders of at least a majority of the outstanding Registrable Securities with
respect to which the provisions of this Agreement have not terminated pursuant to Section
8.13.”

(d) The Investor Rights Agreement is amended by adding a new Section 8.13 as follows:

“8.13 Termination of Rights. Each Investor’s rights, and the rights of each
other holder of Registrable Securities, under this Agreement shall terminate with respect to
such Investor or holder of Registrable Securities upon the earlier to occur of: (x) the date
at which all Registrable Securities held by such holder (and its affiliates, partners,
former partners, members and former members) may be publicly sold in any 90 day period
pursuant to Rule 144 or any successor exemption under the Securities Act and (y) September
11, 2008.”

2. Waiver of Registration Rights. The Investors hereby waive, on behalf of each
holder of Registrable Securities, all of such holders’ rights under Section 4.4 of the Investor
Rights Agreement with respect to the Resale Registration Statement and the inclusion of any or all
of such holders’ Registrable Securities in the Resale Registration Statement.

3. Agreement in Full Force and Effect. Except as specifically amended by this
Amendment, the Investor Rights Agreement remains in full force and effect. Wherever the terms of
this Amendment and the Investor Rights Agreement conflict, this Amendment controls. All references
in the Investor Rights Agreement to “this Agreement” shall mean the Investor Rights Agreement, as
amended hereby.

4. Effective Date. This Amendment shall become effective upon execution by the
Company and the holders of at least two-thirds of the outstanding Registrable Securities
(recognizing that such Registrable Securities constitute at least two-thirds of the shares of
Common Stock issued upon conversion of the Preferred Stock outstanding immediately prior to the
Initial Public Offering).

5. Counterparts. This Amendment may be delivered by facsimile and executed in
counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

1

In witness whereof, the undersigned have executed this Amendment to the
Investor Rights Agreement as of the date first above written.

	 	 	 
	Company:

	 	Memory Pharmaceuticals Corp.

By:/s/ James R. Sulat
	
 
	 	 
	
 
	 	Name: James R. Sulat

Title: President and Chief Executive Officer
	 
	 	 

2

3

	 	 	 
	Investors:	Alta California Partners II L.P.
	 	 	By: Alta California Management Partners II,
	 	 	LLC, Its General Partner
	 	 	By:	/s/ Alix Marduel
	 	 	Name:	 	 	Alix Marduel
	 	 	Title:	Member
	 	 	Alta Embarcadero Partners II LLC
	 	 	By:	/s/ Hilary Strain
	 	 	Name:	 	 	Hilary Strain
	 	 	Title:	Under Power of Attorney

4

	 	 	 
	Investors:	Finsbury Worldwide Pharmaceutical trust
	 	 	By: /s/ Samuel D. Isaly
	 	 	Name:	 	 	Samuel D. Isaly
	 	 	Title:
	 	 	Eaton Vance Worldwide Health Sciences
	 	 	Portfolio
	 	 	By: /s/ Samuel D. Isaly
	 	 	Name:	 	 	Samuel D. Isaly
	 	 	Title:

5

	 	 	 
	Investors:	GIMV
	 	 	By: /s/ Dick Beevsaert
	 	 	Name:	 	 	Dick Beevsaert
	 	 	Title:	Chief Legal Officer
	 	 	By: /s/ Patrick Van Beneden
	 	 	Name:	 	 	Patrick Van Beneden
	 	 	Title:	Executive Vice-President

6

	 	 	 
	Investors:	 	GLSLP Investment LTD
	 	 	By: /s/ Christopher Cochrane
	 	 	Name: Christopher Cochrane
	 	 	Title: Authorised Signatory for Trafalgar
	 	 	Representatives Ltd, Director of GLS
	 	 	LP Investment 1 Limited
	 	 	By: /s/ Pascal Mahieux
	 	 	Name: Pascal Mahieux
	 	 	Title: Authorised Signatory for Trafalgar
	 	 	Representatives Ltd, Director of GLS
	 	 	LP Investment 1 Limited

7

	 	 	 
	Investors:	Healthcare Ventures V L.P.	 
	 	 	By: /s/ Jeffrey Steinberg	 
	 	 	Name:	 	 	Jeffrey Steinberg
	 	 	Title: Administrative Partner of HealthCare
	 	 	Partners V, L.P., The General Partner
	 	 	of HealthCare Ventures V, L.P.

8

	 	 	 
	Investors:	 	Hoffmann-La Roche Inc.
	 	 	By: /s/ Frederick C. Kentz
	 	 	Name: Frederick C. Kentz
	 	 	Title: Vice President

9

	 	 	 
	Investors:	MC Life Science Ventures, Inc.	 
	 	 	By:	 	 	/s/ Tsunehiko Yamagibara
	 	 	Name: Tsunehiko Yamagibara
	 	 	Title: President

10

	 	 	 
	Investors:	Medica II Investment (Israel) LP
	 	 	By: /s/ Dr. E. Geller
	 	 	Name:	 	 	Dr. E. Geller
	 	 	Title: General Partner
	 	 	Medica II Investment International, LP
	 	 	By: /s/ Dr. E. Geller
	 	 	Name: Dr. E. Geller
	 	 	Title:	General Partner
	 	 	Medica II Investments (P.F.) (Israel) L.P.
	 	 	By: /s/ Dr. E. Geller
	 	 	Name: Dr. E. Geller
	 	 	Title: General Partner

11

	 	 	 
	Investors:	Oxford Bioscience Partners II L.P.
	 	 	By: OBP Management II L.P.
	 	 	By: /s/ Jonathan Fleming
	 	 	Name:	 	 	Jonathan Fleming
	 	 	Title:	 	 	
	 	 	Oxford Bioscience Partners (Bermuda) II Limited
	 	 	Partnership
	 	 	By: OBP Management II (Bermuda) Limited
	 	 	Partnership
	 	 	By: /s/ Jonathan Fleming
	 	 	Name:	 	 	Jonathan Fleming
	 	 	Title:	 	 	
	 	 	Oxford Bioscience Partners (Adjunct) II LP
	 	 	By: OBP Management II L.P.
	 	 	By: /s/ Jonathan Fleming
	 	 	Name:	 	 	Jonathan Fleming
	 	 	Title:	 	 	
	 	 	Oxford Bioscience Partners (GS-Adjunct) II LP
	 	 	By: OBP Management II L.P.
	 	 	By: /s/ Jonathan Fleming
	 	 	Name:	 	 	Jonathan Fleming
	 	 	Title:	 	 	
	 	 	Oxford Bioscience Partners II (Annex) LP
	 	 	By: OBP Management II L.P.
	 	 	By: /s/ Jonathan Fleming
	 	 	Name:	 	 	Jonathan Fleming
	 	 	Title:	 	 	

12

	 	 	 
	Investors:	 	Rho Management Trust II
	 	 	By: Rho Capital Partners, Inc., Investment
	 	 	Advisors
	 	 	By: /s/ Jeffrey I. Martin
	 	 	Name: Jeffrey I. Martin
	 	 	Title: Attorney In Fact

13

	 	 	 
	Investors:	 	S.R. One Limited
	 	 	By: /s/ Donald F. Parman
	 	 	Name: Donald F. Parman
	 	 	Title: Vice President & Secretary

	 	 	 
	

Investors:            Venrock Associates     }
                               By: /s/ Anthony B. Evnin

                               Name:  Anthony B. Evnin         }
                               Title:    General Partner       }
                               Venrock Associates II, L.P.
                               By: /s/ Anthony B. Evnin

                               Name:  Anthony B. Evnin         }
                               Title:    General Partner       }
                               Venrock Entrepreneuers Fund, L.P.
                               By: /s/ Anthony B. Evnin

                               Name:  Anthony B. Evnin
                               Title:    Member
Investors:	Venrock Associates
	 	 	By: /s/ Anthony B. Evnin
	 	 	Name:	 	 	Anthony B. Evnin
	 	 	Title:	General Partner
	 	 	Venrock Associates II, L.P.
	 	 	By: /s/ Anthony B. Evnin
	 	 	Name:	 	 	Anthony B. Evnin
	 	 	Title:	General Partner
	 	 	Venrock Entrepreneuers Fund, L.P.
	 	 	By: /s/ Anthony B. Evnin
	 	 	Name:	 	 	Anthony B. Evnin
	 	 	Title: Member

14EX-10.183

Exhibit 10.183

SHARES EXCHANGE AGREEMENT

This Shares Exchange Agreement (this “Agreement”) is entered into between The Immune Response
Corporation, a Delaware corporation (the “Company”), and Cheshire Associates LLC, a Delaware
limited liability company (“Cheshire”), as of September 21, 2005 (the “Effective Date”).

The parties acknowledge that (a) Cheshire owns 688,146 shares of Series A Convertible
Preferred Stock of the Company (the “Preferred Shares”), (b) the closing sale price of the
Company’s common stock on September 21, 2005, as reported by The Nasdaq Stock Market, was $0.46,
(c) the accrued dividends on the Preferred Shares through September 21, 2005 total $637,241.45, and
(d) pursuant to the terms of the governing charter document, the conversion price of the Preferred
Shares is scheduled to decline to $0.4987 on April 8, 2006.

1. All the Preferred Shares are hereby exchanged, pursuant to Section 3(a)(9) of the
Securities Act, for 9,643,060 shares of newly-issued common stock of the Company (the “Common
Shares”). The Common Shares shall have the same registration rights, if any, as had been enjoyed
by the common shares underlying the Preferred Shares. The Company agrees to promptly deliver the
Common Shares to Cheshire against return of the Preferred Shares to the Company for cancellation.
It is understood that the exchange contemplated by this Agreement also satisfies all claims of
Cheshire for accumulated and to-be-accumulated dividends on the Preferred Shares.

2. This Agreement and the exchange contemplated hereby shall cause no antidilution adjustment
or other effect of any kind on any Company securities beneficially owned by Cheshire. To that
extent, the terms of each of such other securities are hereby amended. To the extent such
amendment is impossible or impractical, Cheshire hereby waives the benefit of such adjustment or
other effect, for itself and for its successors and assigns, and reverts and relinquishes such
rights to the Company.

3. This Agreement may not be amended or waived except in a writing signed by both parties.
Both parties agree to cooperate and to do all acts and sign all documents necessary or desirable in
order to more perfectly evidence or effectuate the intent of this Agreement. This Agreement shall
be governed by, and construed and interpreted in accordance with, the laws of the State of New
York. This Agreement and those documents expressly referred to herein embody the complete
agreement and understanding between the parties and supersede and preempt any pre-Effective-Date
understandings, agreements, or representations by or between the parties, written or oral, which
may have related to the subject matter hereof in any way.

THE IMMUNE RESPONSE CORPORATION

By:

Chief Executive Officer

CHESHIRE ASSOCIATES LLC

By:

Nonmember Manager

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]